"Adenoid cystic carcinoma"

Aurora kinase A expression in pleomorphic adenoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma of salivary glands: an immunohistochemical study. Aurora kinase A (AurkA) plays a vital role in mitosis and is therefore critical in tumors development and progression. There are a few studies on AurkA expression in salivary gland tumors. The aim of the present study was to evaluate the expression pattern of AurkA in the most common benign and malignant salivary gland tumors by immunohistochemistry. In this retrospective cross-sectional study, 68 cases including 25 pleomorphic adenomas (PAs), 21 adenoid cystic carcinomas (ADCa), 15 mucoepidermoid carcinomas (MEC), and 7 normal salivary glands (NSG) were enrolled from the archive of the Department of Pathology of Shiraz School of Dentistry

Distinct patterns of osteoradionecrosis after photon-based radiotherapy and carbon ion radiotherapy for unresectable adenoid cystic carcinoma of the head and neck: case series from two institutions. To present the clinical outcomes of two series of patients treated with carbon-ion radiotherapy (CIRT) and definitive photon radiotherapy (RT) for adenoid cystic carcinoma of the head and neck (HN

Apolipoprotein D is crucial for promoting perineural invasion in salivary adenoid cystic carcinoma. Perineural invasion (PNI) is a prevalent phenomenon in salivary adenoid cystic carcinoma (SACC). Nevertheless, the regulatory mechanism of PNI is largely elusive. We detected Apolipoprotein D (ApoD) expression and further determined its role in SACC progression. Subsequently, the contributions

Primary pulmonary adenoid cystic carcinoma: A study of clinicopathological features and molecular alterations in twenty-one cases. Primary pulmonary adenoid cystic carcinoma (PACC) is a rare malignant tumor. Despite the growing sophistication of ACC research, scant studies have delved into the unique molecular alterations of ACC originating from the lung and the clinical features associations

Prognostic factors and survival in patients with adenoid cystic carcinomas of the submandibular gland: a retrospective study of 38 cases from a single centre. A retrospective review was performed to evaluate the prognostic factors and survival of patients with submandibular gland adenoid cystic carcinomas (ACCs), covering the period January 2006-December 2022. Thirty-eight patients were

Tumor immune microenvironment in adenoid cystic carcinoma of the lacrimal gland: relationship with histopathology and prognosis. To quantitatively investigate the pathological subtypes of lacrimal gland adenoid cystic carcinoma (LGACCs), the tumor immune microenvironment in each pathological subtype, and the relation to survival. In this retrospective study, the tumor subtype was determined by H

Adjuvant Radiotherapy in pT1-2N0M0 Head and Neck Adenoid Cystic Carcinoma. Evidence regarding the indications and survival benefit of adjuvant radiotherapy (aRT) in pT1-2N0M0 head and neck adenoid cystic carcinoma (HNAdCC) is inconclusive. Lower-staged, node-negative HNAdCC therefore represents a rare, moderate-risk disease category with high variation in adjuvant management depending on patient

Personalized treatment strategies for breast adenoid cystic carcinoma: A machine learning approach. Breast adenoid cystic carcinoma (BACC) is a rare subtype of breast cancer that accounts for less than 0.1 % of all cases. This study was designed to assess the efficacy of various treatment approaches for BACC and to create the first web-based tool to facilitate personalized treatment decisions

Characterizing Adenoid Cystic Carcinoma of the Middle Ear-A Rare Entity. To characterize patient demographics, tumor features, treatment patterns, and survival outcomes of adenoid cystic carcinoma of the middle ear. Retrospective review of the Surveillance, Epidemiology, and End Results Database of the National Cancer Institute for all cases of histopathologically confirmed adenoid cystic carcinoma of the middle ear as the primary location. Twenty-one patients with adenoid cystic carcinoma of the middle ear were identified. Patients had a median age of 61 years (range 16-86) and were more commonly female (57.1%) and Caucasian (85.7%). Tumors had a median size of 11 mm (range 5-22) with disease involvement most frequently locally (70%), followed by distant (20%), then regional disease (10

Molecular Profiling of Sinonasal Adenoid Cystic Carcinoma: Canonical and Noncanonical Gene Fusions and Mutation. Adenoid cystic carcinomas (AdCC) of salivary gland origin have long been categorized as fusion-defined carcinomas owing to the almost universal presence of the gene fusion MYB::NFIB, or less commonly MYBL1::NFIB. Sinonasal AdCC is an aggressive salivary gland malignancy

Salivary gland adenoid cystic carcinoma in the U.S population: Importance of grade, site of metastases, and adjuvant radiation for survival. Adenoid cystic carcinoma (AdCC) is a rare and relatively heterogenous salivary gland malignancy, for which there is debate regarding grading, and clinical prognostic factors, including the role of adjuvant radiotherapy. Surveillance, Epidemiology, and End

Adenoid cystic carcinoma of the Bartholin's gland is underpinned by MYB- and MYBL1- rearrangements. Adenoid cystic carcinoma (AdCC) of the Bartholin's gland (AdCC-BG) is a very rare gynecologic vulvar malignancy. AdCC-BGs are slow-growing but locally aggressive and are associated with high recurrence rates. Here we sought to characterize the molecular underpinning of AdCC-BGs. AdCC-BGs (n = 6

Molecular profiling and the impact of treatment on outcomes in adenoid cystic carcinoma (ACC) type-I and II. Adenoid cystic carcinoma (ACC) is an uncommon salivary gland cancer with no approved therapies available to treat advanced, incurable disease. Recent molecular profiling efforts have identified two important subtypes: the more aggressive ACC-I is characterized by Notch pathway alterations

Neoadjuvant Intra-arterial Cytoreductive Chemotherapy Improves Outcomes in Lacrimal Gland Adenoid Cystic Carcinoma. Lacrimal gland adenoid cystic carcinoma (LGACC) has historically been associated with a poor prognosis even with localized disease, with a survival of 56% at 5 years. In 1988, we treated the first patient with neoadjuvant intra-arterial cytoreductive chemotherapy (IACC). Since

Impact of NOTCH1 expression in primary breast adenoid cystic carcinoma. Adenoid cystic carcinoma (AdCC) originates from salivary-type like glands in the head and neck, lung, and breast. AdCC shows chromosomal translocation, resulting in fusion and overexpression of MYB. Recently, NOTCH1 pathway alteration has been recognised in a subset of patients with salivary gland AdCC and has been shown

MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers. Adenoid cystic carcinoma is a rare subtype of triple-negative breast carcinoma. These low-grade tumours, which are treated by simple mastectomy and have an excellent prognosis compared to other triple-negative breast carcinomas. Solid-variant adenoid cystic carcinomas have basaloid features and are difficult to distinguish morphologically from other triple-negative breast cancers. Breast adenoid cystic carcinoma exhibits MYB protein overexpression, which can be detected by immunohistochemistry (IHC). We compared the IHC expression of MYB in solid-variant adenoid cystic carcinoma with that in other triple

Prognostic Impact of Notch1 Intracellular Domain, P63, and c-MYC in Lacrimal Gland Adenoid Cystic Carcinoma. We assessed whether NICD1 expression, c-MYC expression, and P63 expression by immunohistochemistry (IHC) correlate with prognosis and high-risk clinicopathological features in lacrimal gland adenoid cystic carcinoma (ACC). Records of patients with lacrimal gland ACC who underwent surgery

Discovery of Novel TULP4/ACTN4/EWSR1/ACTB::MYB and ESRRG::DNM3 Fusions Expands Molecular Landscape of Adenoid Cystic Carcinoma Beyond Fusions Between MYB/MYBL1 and NFIB Genes. Adenoid cystic carcinoma (AdCC) is one of the most common salivary gland malignancies and occurs in all major and minor salivary gland and seromucous gland sites. AdCCs of salivary gland origin have long been categorized

Outcomes of patients in nasopharyngeal adenoid cystic carcinoma in the IMRT era: a single-center experience. Nasopharyngeal adenoid cystic carcinoma (NACC) is a rare malignancy with special biological features. Controversies exist regarding the treatment approach and prognostic factors in the IMRT era. This study aimed to evaluate the long-term outcomes and management approaches in NACC. Fifty

Long-term outcomes after particle radiation therapy in patients with nasopharyngeal adenoid cystic carcinoma. Nasopharyngeal adenoid cystic carcinoma (NACC) is a relatively rare salivary gland tumor that is generally associated with poor outcomes. High-dose radiotherapy is a key treatment for patients with NACC. This study reported the long-term efficacy and safety of particle beam radiation